On June 7, 2018 Atreca, Inc., a biotechnology company focused on developing novel therapeutics based on a deep
understanding of the human immune response, reported that Norman Michael Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer at Atreca, will deliver a presentation highlighting progress of the Company’s advancing immuno- oncology pipeline during the 2018 World Preclinical Congress (WPC) Annual Meeting, which is taking place at Westin Copley Place in Boston, MA, June 18-21, 2018 (Press release, Atreca, JUN 7, 2018, View Source [SID1234527228]). Dr. Greenberg will report on results of Atreca’s R&D engine, Immune Repertoire Capture (IRC), to identify therapeutic antibodies for development based on patients’ responses to cancer immunotherapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The power of our IRC technology lies in its ability to accurately discover anti-ˇtumorantibodies in patients who have achieved successful outcomes following anti-cancer treatments, such as checkpoint inhibitor immunotherapy," said John A. Orwin, Atreca’s President and Chief Executive Officer. "As highlighted in this promising research, our
recombinantly expressed antibodies were able to cause tumor regression and induce durable immunity in in vivo preclinical cancer models. We are delighted to report on the progress of this and other key research at Atreca as we continue to advance our pipeline toward entry into the clinic next year."

Details regarding the oral presentation are available on the WPC website and are also
as follows:

Presentation Title: Discovery and Characterization of Functional Anti-ˇTumor Antibodies from Non-ˇProgressing Cancer Patients Undergoing Immunotherapy

Session Title: New Targets and Approaches;; Preclinical Strategies, Models & Tools in Oncology: Executive Summit
Presentation Date & Time: Tuesday, June 19, 2018, 11:05 AM ET
Location: Essex South Room, Westin Copley Place